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Antithymocyte globulins (ATG) such as rabbit ATG (Thymo-
globulin) are immunosuppressive agents known to deplete T cells,
and there is increasing evidence that they may also affect T cell
migration. In this study, we sought to determine if Thymoglobulin
affects L-selectin-dependent lymphocyte binding to lymph node
high endothelial venules (HEV), the ﬁrst step in migration of
lymphocytes to lymph nodes. Human peripheral blood lympho-
cytes were collected by Ficoll centrifugation of citrated blood and
T cells were isolated by magnetic bead separation. T cells were
exposed to Thymoglobulin at 10, 20, 30, 40, and 50 ug/ml for 30
minutes at 4° C; controls consisted of puriﬁed rabbit immunoglob-
ulin at identical concentrations. The capacity of T cells to engage
HEV was measured by Stamper-Woodruff assay. Additionally,
parallel plate ﬂow chamber studies were performed under physio-
logic shear stress conditions to measure T cell binding to L-
selectin ligands expressed on the hematopoietic cell line, KG1a.
Incubation of T cells with Thymoglobulin led to a dose-dependent
decrease in binding to HEV, with complete abrogation at 50
ug/ml. Similarly, Thymoglobulin blunted L-selectin-mediated
binding interactions in parallel plate ﬂow studies. Flow cytometry,
performed using a variety of anti-L-selectin mAb showed, ironi-
cally, that incubation of T cells with Thymoglobulin resulted in an
increase in the percent marker cells and the mean channel ﬂuo-
rescence for L-selectin epitopes targeted by mAbs TQ-1 and
LAM1-116, with no change in the levels of the DREG56 epitope.
These changes were speciﬁc for L-selectin, as there were no
changes in expression of VLA-4 using the same conditions. Im-
portantly, as shown by analysis of Thymoglobulin immunoprecipi-
tates of biotinylated T cells, Thymoglobulin does not directly
recognize L-selectin. These ﬁndings indicate that the effects of
Thymoglobulin on L-selectin function are not related to decreased
surface expression, but appear to be related to changes in L-
selectin topography affecting L-selectin’s capacity to engage its
ligand(s). Further studies are in progress to deﬁne the nature of
these changes and how modulation of L-selectin topography is
achieved by Thymoglobulin. Operationally, changes in L-selectin
function could have profound implications in the ability of circu-
lating lymphocytes to enter lymphoid tissues, inhibiting appropri-
ate antigen-recognition and subsequent generation of immune
responses.
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NEIC BONE MARROW TRANSPLANTATION
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Background: “Mini” transplants using non-myeloablative con-
ditioning can avoid early post-transplant toxicity associated with
myeloablative conditioning prior to allogeneic hematopoietic pro-
genitor cell transplantation (HPCT), but graft-versus-host-disease
(GvHD) and graft rejection remain clinical problems. We previ-
ously found that low-dose busulfan conditioning and costimulatory
blockade using anti-CD154 monoclonal antibody (mAb) were suf-
ﬁcient to establish stable mixed chimerism without GvHD when
transplanting moderate doses of T cell depleted bone marrow
(TCD-BM) from MHC fully mismatched donors (Adams et al,
J Immunol 167:1103, 2001). Additionally, several groups have
shown that apoptotic cells can contribute to immune tolerance in
HPCT. Therefore, in an effort to enhance donor chimerism and
graft-versus-leukemia activity, we evaluated the ability of different
preparations of donor lymphocytes to provide a tolerizing effect
and facilitate stable donor chimerism when administered prior to
the BM graft. Methods: In B63B10BR and BALB/c3B6 MHC
fully mismatched transplant pairs, donor lymphocytes were treated
ex-vivo with different immunosuppressive regimens (ﬂudarabine,
psoralen-UVA, -irradiation) and used as tolerizing DLI 6 days
prior to HPCT, co-administered with anti-CD154 mAb and low-
dose busulfan conditioning. We also compared the use of donor
lymphocytes that had been enriched for, or depleted of, T cells or
CD11b/CD11b subsets as tolerizing DLI in the same “mini”-
transplant setting. Results: Long-term mixed-chimerism without
GvHD was enhanced by pre-transplant administration of viable
allogeneic splenocytes (Table 1). Unexpectedly, the use of apopto-
tic/necrotic donor splenocytes resulted in diminished donor en-
graftment. Puriﬁed splenic T cells more potently enhanced donor
chimerism compared to unfractionated splenocytes, T cell de-
pleted splenocytes, or the CD11b and CD11b fractions of
donor splenocytes. In a leukemia model, the survival of recipients
with mixed-chimerism following low-dose busulfan and co-stimu-
latory blockade was enhanced by viable post-transplant donor T
cell infusions. Conclusions: Host tolerance of donor cells follow-
ing non-myeloablative conditioning and co-stimulatory blockade is
an active process enhanced by viable donor immune cells. The
diminished donor chimerism obtained with apoptotic/necrotic do-
nor splenocytes suggests that dying cells interfere with the donor-
speciﬁc tolerance generated by anti-CD154 mAb.
Conditioning and Transplantation (B63B10BR)
Donor Chimerism (%)
(no. engraftment
[donor cells >1%] mice/
all mice in the group)
Tolerizing DLI
(3107) i.v. at d-6
	CD154
mAb (i.v. at
d-7, 6,
4, 2, 0,
& 6)
Busulfan
(i.p at d-1)
TCD-BM
(i.v at d0) d  30 d  60 d  160
No Tolerizing DLI no 20 mg/kg 2107 0 0 0
No Tolerizing DLI 500g 20 mg/kg 2107 42 10 35 21 44 20
Un-manipulated SP 500g 20 mg/kg 2107 65 7* 52 17* 79 7*
CD3() SP 500g 20 mg/kg 2107 ND 68 6* ND
CD11b() SP 500g 20 mg/kg 2107 ND 43 4 ND
Fludarabine
treated-SP
500g 20 mg/kg 2107 45 6 ND 52 4
PUVA treated-SP 500g 20 mg/kg 2107 33 13 ND 47 23
Irradiated-SP (7.5 Gy) 500g 20 mg/kg 2107 28 24* ND 42 22
Irradiated-SP (15 Gy) 500g 20 mg/kg 2107 12 15* ND 20 17*
Irradiated-SP (30 Gy) 500g 20 mg/kg 2107 2 4*
(5/10) no.
ND 4 7*
(4/10) no.
*P .05 vs recipients of No Tolerizing DLI with 
CD154 mAb at
same time point.
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RAPID IMMUNE RECONSTITUTION AND COMPLETE DONOR CHIMER-
ISM AFTER NON-MYELOABLATIVE ALLOGENEIC PERIPHERAL BLOOD
STEM CELL TRANSPLANTATION (NMSCT) IN PEDIATRIC PATIENTS
(PTS) WITH MALIGNANCY
Fry, T.J.1, Rager, A.1,2, Hakim, F.3, Love, C.1, Layton, P.1,
Fowler, D.3, Bishop, M.R.3, Gress, R.3, Mackall, C.L.1, Wayne, A.S.1 1.
Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, MD; 2. Duke
University School of Medicine, Durham, NC; 3. Experimental Trans-
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Background: Experience with NMSCT for pediatric cancer is
limited. Compared to adults, children and adolescents have less
immune depletion and improved reconstitution after chemother-
apy, which might increase the risk of graft rejection or mixed
chimerism. On the other hand, preserved host thymic function
might enhance donor-derived immune recovery. We postulated
that pre-transplant immune depletion followed by T cell replete
NMSCT would facilitate donor engraftment and enhance post-
transplant immune reconstitution. Methods: We piloted a novel
regimen in 21 pediatric pts (median age 14, range 4–21) with
high-risk hematologic malignancies and sarcomas. Fludarabine-
based induction chemotherapy was administered for disease con-
trol and targeted CD4 count reduction. Pre-transplant condition-
ing consisted of cyclophosphamide (1200 mg/m2/day) and
ﬂudarabine (30 mg/m2/day)  4 days plus melphalan (100 mg/m2
 1 dose in sarcoma pts). Grafts consisted of G-CSF mobilized
unmodiﬁed peripheral blood stem cells from 5-6/6 HLA-matched
ﬁrst-degree relatives (median CD34 dose 11.7  106/kg, range
4.4–19.1; median CD3 dose 416  106/kg, range 228–815). Cy-
closporine was used for GVHD prophylaxis. Results: Induction
therapy dramatically reduced CD4 counts. Donor-derived engraft-
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